AB0449 Coupling Anti-SM Antibody Detection and Anti-Chromatin Antibody Detection Improves The Diagnosis and Prognosis of Systemic Lupus Erythematosus. (15th July 2016)

• Record Type: Journal Article
• Authors: Carvajal Alegria, G.; Capaldo, C.; Roguedas-Contios, A.-M.; Hanrotel-Saliou, C.; Pluchon, M.; Pasquier, E.; Jousse-Joulin, S.; Renaudineau, Y.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 1060
• Page End: 1060
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.3426
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Autoantibody (Ab) detection including anti-nuclear Ab (ANA) plus anti-dsDNA/Chromatin Ab and/or anti-Sm Ab is central in the diagnosis and prognosis of systemic lupus erythematosus (SLE) and several methods can be used to detect them. Objectives: Our objective was to compare diagnostic accuracy for several anti-dsDNA Ab, anti-chromatin Ab and anti-Sm Ab detection. Methods: Accordingly, we compared different methods for anti-dsDNA Ab [indirect immunofluorescence using Crithidia Luciliae (CLIFT), anti-dsDNA by ELISA, anti-dsDNA by chemiluminescence (CLIA; IDS-ISYS, IDS) and anti-chromatin Ab (dsDNA-NCX, Euroimmun)] and anti-Sm Ab by ELISA (Immuno concept) and by CLIA (IDS-ISYS, IDS)]. The evaluation was performed in 49 SLE and 98 autoimmune disease controls including rheumatoid arthritis, scleroderma, vasculitis and Sjögren's syndrome. Results: In SLE patients, Ab sensitivity (and specificity) was 97.9% for AAN, 61.2% (92.9%) for anti-chromatin Ab, 36.7% (93 9%) for anti-dsDNA Ab by CLIA, 32.6% (95.9%) for anti-dsDNA Ab by ELISA, and 30.6% (100%) by CLIFT. For anti-Sm Ab, CLIA improved its detection (sensibility 18.4% versus 8.2% by ELISA; specificity 100% both). The best associations were found for anti-chromatin Ab and CLIFT (sensitivity 67.3% and specificity 91.8%), and for anti-chromatin and anti-Sm Abs by CLIA (sensitivity 53.1% and specificity 95.2%). Several associations were identified, including, for anti-chromatin Ab, articular [Odds ratio (OR)=28, 41; p=0, 002] and cardio vascular disease [OR=9, 47; p=0, 032], plus leucopenia [OR=13, 72; p=0, 049]; and for anti-Sm Ab by CLIA lupus glomerulonephritis [OR =5.0, p=0.05], and pleuropulmonary manifestations [OR =25.3; p=0.004]. Conclusions: Combining anti-chromatin Ab detection by ELISA and anti-Sm Ab detection by CLIA contribute to improve the diagnosis and the prognosis of SLE. Disclosure of Interest: None declared